Sun Pharma share price has plunged 3% and is presently trading at Rs 1,794.3.
Meanwhile, the BSE HEALTHCARE index is at 43,691.3 (down 1.2%).
Among the top losers in the BSE HEALTHCARE index today are J.B.Chemicals (down 3.6%) and CAPLIN POINT (down 3.1%).
KIMS (up 2.3%) and MAX HEALTHCARE INSTITUTE (up 1.7%) are among the top gainers today.
Over the last one year, Sun Pharma has moved up from Rs 1,088.7 to Rs 1,794.3, registering a gain of Rs 705.6 (up 64.8%).
On the other hand, the BSE HEALTHCARE index has moved up from 27,271.8 to 43,691.3, registering a gain of 60.2% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 230.2%), SUVEN PHARMACEUTICALS (up 125.4%) and Glenmark Pharma (up 122.6%).
Dear Reader: If You Invest in Midcap Stocks, this is for You
The BSE Sensex is at 78,952.1 (down 1.1%).
The top losers among the BSE Sensex today are Reliance Ind. (down 2.5%) and MUNDRA PORT & SEZ (down 2.3%). The most traded stocks in the BSE Sensex are Tata Steel and Reliance Ind..
In the meantime, NSE Nifty is at 24,080.8 (down 0.9%). Bajaj Auto and IOC are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 63,874.9 to 78,952.1, registering a gain of 15,077.1 points (up 23.6%).
Sun Pharma net profit grew 26.2% YoY to Rs 30,307 million for the quarter ended September 2024, compared to a profit of Rs 24,008 million a year ago. Net sales rose 9.0% to Rs 132,914 million during the period as against Rs 121,924 million in July-September 2023.
For the year ended March 2024, Sun Pharma reported 12.7% increase in net profit to Rs 96,484 million compared to net profit of Rs 85,608 million during FY23. Revenue of the company grew 10.5% to Rs 484,969 million during FY24.
The current Price to earnings ratio of Sun Pharma, based on rolling 12 month earnings, stands at 38.7.
Equitymaster requests your view! Post a comment on "Sun Pharma Plunges 3%; BSE HEALTHCARE Index Down 1.2%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!